Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 2
2001 7
2002 2
2003 1
2004 1
2005 2
2006 2
2007 4
2008 3
2009 5
2010 1
2011 6
2012 1
2013 2
2014 2
2015 4
2016 4
2017 10
2018 11
2019 9
2020 7
2021 11
2022 7
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, Hunter R, Bunce C, Nathwani N, Barton K; LiGHT Trial Study Group. Gazzard G, et al. Ophthalmology. 2023 Feb;130(2):139-151. doi: 10.1016/j.ophtha.2022.09.009. Epub 2022 Sep 17. Ophthalmology. 2023. PMID: 36122660 Free article. Clinical Trial.
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial has shown selective laser trabeculoplasty (SLT) to be clinically and cost-effective as a primary treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT) at 3 years. ...At …
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial has shown selective laser trabeculoplasty (SLT) to …
A Global Assessment of Eye Health and Quality of Life: A Systematic Review of Systematic Reviews.
Assi L, Chamseddine F, Ibrahim P, Sabbagh H, Rosman L, Congdon N, Evans J, Ramke J, Kuper H, Burton MJ, Ehrlich JR, Swenor BK. Assi L, et al. JAMA Ophthalmol. 2021 May 1;139(5):526-541. doi: 10.1001/jamaophthalmol.2021.0146. JAMA Ophthalmol. 2021. PMID: 33576772 Free PMC article. Review.
OBJECTIVE: To examine the association between vision impairment or eye disease and quality of life, and the outcome of ophthalmic interventions on quality of life globally and across the life span, through an umbrella review or …
OBJECTIVE: To examine the association between vision impairment or eye disease and quality of life, and the outcome of …
Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS).
King AJ, Hudson J, Fernie G, Kernohan A, Azuara-Blanco A, Burr J, Homer T, Shabaninejad H, Sparrow JM, Garway-Heath D, Barton K, Norrie J, McDonald A, Vale L, MacLennan G; TAGS Study Group. King AJ, et al. BMJ. 2021 May 12;373:n1014. doi: 10.1136/bmj.n1014. BMJ. 2021. PMID: 33980505 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether primary trabeculectomy or primary medical treatment produces better outcomes in term of quality of life, clinical effectiveness, and safety in patients presenting with advanced glaucoma. DESIGN: Pragmatic multicen …
OBJECTIVE: To determine whether primary trabeculectomy or primary medical treatment produces better outcomes in term of quality …
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M; LiGHT Trial Study Group. Gazzard G, et al. Lancet. 2019 Apr 13;393(10180):1505-1516. doi: 10.1016/S0140-6736(18)32213-X. Epub 2019 Mar 9. Lancet. 2019. PMID: 30862377 Free PMC article. Clinical Trial.
We compared the two. METHODS: In this observer-masked, randomised controlled trial treatment-naive patients with open angle glaucoma or ocular hypertension and no ocular comorbidities were recruited between 2012 and 2014 at six UK hospitals. ...Analysi …
We compared the two. METHODS: In this observer-masked, randomised controlled trial treatment-naive patients with open a …
Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial.
Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, Scotland G, Javanbakht M, Cochrane C, Norrie J; EAGLE study group. Azuara-Blanco A, et al. Lancet. 2016 Oct 1;388(10052):1389-1397. doi: 10.1016/S0140-6736(16)30956-4. Lancet. 2016. PMID: 27707497 Free article.
BACKGROUND: Primary angle-closure glaucoma is a leading cause of irreversible blindness worldwide. ...Eligible patients were aged 50 years or older, did not have cataracts, and had newly diagnosed primary angle closure with intraocular pressure …
BACKGROUND: Primary angle-closure glaucoma is a leading cause of irreversible blindness worldwide. ...Eligible patients …
Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Barton K, Wormald R, Morris S, Hunter R, Rubin G, Buszewicz M, Ambler G, Bunce C; LiGHT Trial Study Group. Gazzard G, et al. Br J Ophthalmol. 2018 May;102(5):593-598. doi: 10.1136/bjophthalmol-2017-310877. Epub 2017 Sep 13. Br J Ophthalmol. 2018. PMID: 28903966 Clinical Trial.
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open-angle glaucoma (POAG) …
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial aims to establish whether initial treatment with selectiv …
Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Morris S, Buszewicz M. Gazzard G, et al. Health Technol Assess. 2019 Jun;23(31):1-102. doi: 10.3310/hta23310. Health Technol Assess. 2019. PMID: 31264958 Free PMC article. Clinical Trial.
We also compared the clinical effectiveness and cost-effectiveness of the two pathways. DESIGN: A 36-month pragmatic, unmasked, multicentre randomised controlled trial. SETTINGS: Six collaborating specialist glaucoma clinics across the UK. ...An altern …
We also compared the clinical effectiveness and cost-effectiveness of the two pathways. DESIGN: A 36-month pragmatic, unmasked, multicentre …
Juvenile idiopathic arthritis-associated uveitis.
Sen ES, Ramanan AV. Sen ES, et al. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):517-534. doi: 10.1016/j.berh.2018.01.002. Epub 2018 Feb 26. Best Pract Res Clin Rheumatol. 2017. PMID: 29773271 Review.
The uveitis is potentially sight-threatening and thus carries a considerable risk of morbidity with associated reduction in quality of life. The commonest form of uveitis seen in association with JIA is chronic anterior uveitis, which is almost always asympto …
The uveitis is potentially sight-threatening and thus carries a considerable risk of morbidity with associated reduction in quality …
Systematic Review of Knowledge Assessments for Glaucoma Patients.
Peralta E, Muir KW, Rosdahl JA. Peralta E, et al. Semin Ophthalmol. 2018;33(3):377-388. doi: 10.1080/08820538.2016.1247180. Epub 2016 Dec 14. Semin Ophthalmol. 2018. PMID: 27960573 Review.
Thirteen studies that have measured and described glaucoma patient knowledge using questionnaires were identified from the literature, including cross-sectional studies of disease knowledge and studies evaluating the efficacy of an educational intervention, both randomi …
Thirteen studies that have measured and described glaucoma patient knowledge using questionnaires were identified from the literature …
A Review of the Prevalence of Ophthalmologic Diseases in Native American Populations.
Miller AM, Gill MK. Miller AM, et al. Am J Ophthalmol. 2023 Oct;254:54-61. doi: 10.1016/j.ajo.2023.06.010. Epub 2023 Jun 17. Am J Ophthalmol. 2023. PMID: 37336384 Review.
Visual impairment is a barrier to communication, interferes with academic and social success, and decreases overall quality of life. The prevalence of ocular pathology could serve as an indicator of health and social disparities. Therefore, the objective of t …
Visual impairment is a barrier to communication, interferes with academic and social success, and decreases overall quality of …
113 results